Market research
VNRX VolitionRx Limited
AMEX USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 16.566
- Dividend yield
- Not available
- Beta
- 1.14
Profile
Company facts
- Exchange
- AMEX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US9286612067
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 16.566
- Dividend yield
- Not available
- Beta
- 1.14
About
About VolitionRx Limited
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the VNRX discussion.
5 years, 4 months ago
VolitionRx Limited is currently in a long term downtrend where the price is trading 17.1% below its 200 day moving average.
From a valuation standpoint, the stock is 851.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 12741.3.
VolitionRx Limited's total revenue rose by inf% to $7K since the same quarter in the previous year.
Its net income has dropped by 44.4% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 413.9% to $9M since the same quarter in the previous year.
Based on the above factors, VolitionRx Limited gets an overall score of 2/5.